Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Frydenberg

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
European Urology|September 20, 2014
Defining a standard set of patient-centered outcomes for men with localized prostate cancerNeil E Martin, Laura Massey, Caleb Stowell, et al.
The Journal of Urology|May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerLouise Emmett, Nathan Papa, Thomas A Hope, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2021
Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survivalKen Chow, Justin Bedő, Andrew Ryan, et al.
Genome Research|April 14, 2018
Enduring epigenetic landmarks define the cancer microenvironmentRuth Pidsley, Mitchell G Lawrence, Elena Zotenko, et al.
Nature Communications|January 10, 2017
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectoriesRenea A Taylor, Michael Fraser, Julie Livingstone, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
European Urology|September 20, 2014
Defining a standard set of patient-centered outcomes for men with localized prostate cancerNeil E Martin, Laura Massey, Caleb Stowell, et al.
The Journal of Urology|May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerLouise Emmett, Nathan Papa, Thomas A Hope, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2021
Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survivalKen Chow, Justin Bedő, Andrew Ryan, et al.
Genome Research|April 14, 2018
Enduring epigenetic landmarks define the cancer microenvironmentRuth Pidsley, Mitchell G Lawrence, Elena Zotenko, et al.
Nature Communications|January 10, 2017
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectoriesRenea A Taylor, Michael Fraser, Julie Livingstone, et al.
European Urology Oncology|December 7, 2023
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate CancerJames P Buteau, Daniel Moon, Michael T Fahey, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Pageof 19